{
 "query": "ethinyl estradiol / etonogestrel",
 "ingredient": "ethinyl estradiol / etonogestrel",
 "slug": "ethinyl-estradiol-etonogestrel",
 "rxcui": "352376",
 "brands": [
  "EluRyng",
  "Enilloring",
  "Haloette",
  "NuvaRing"
 ],
 "names": [
  "ethinyl estradiol / etonogestrel"
 ],
 "components": [
  {
   "ingredient": "ethinyl estradiol",
   "slug": "ethinyl-estradiol",
   "grade": "C",
   "total": 66,
   "scores": {
    "safety": "D",
    "evidence": "F",
    "regulatory": "A",
    "conflict": "A",
    "options": "C"
   },
   "boxed": true,
   "controlled": false,
   "first_approval_fmt": "06/25/1943",
   "first_approval": "19430625"
  },
  {
   "ingredient": "etonogestrel",
   "slug": "etonogestrel",
   "grade": "D",
   "total": 60,
   "scores": {
    "safety": "D",
    "evidence": "F",
    "regulatory": "B",
    "conflict": "C",
    "options": "C"
   },
   "boxed": true,
   "controlled": false,
   "first_approval_fmt": "07/17/2006",
   "first_approval": "20060717"
  }
 ],
 "classes": [],
 "alternatives": [],
 "label": {},
 "faers": null,
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "first_approval": "19430625",
  "first_approval_fmt": "",
  "anda": 0,
  "nda": 0,
  "rems": true,
  "labeling_recent": 0
 },
 "trials": null,
 "pubmed": null,
 "payments": {
  "year": "2024",
  "usd": 6936.48,
  "records": 447,
  "by_name": [
   [
    "NuvaRing",
    6936.48
   ]
  ],
  "names_checked": [
   "ethinyl estradiol / etonogestrel",
   "EluRyng",
   "Enilloring",
   "Haloette",
   "NuvaRing"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 8012,
  "beneficiaries": 2950,
  "spend": 1571040.17,
  "by_brand": [
   {
    "brand": "Etonogestrel-Ethinyl Estradiol",
    "claims": 3388,
    "per_claim": 196.29206021,
    "is_generic": false
   },
   {
    "brand": "Eluryng",
    "claims": 2065,
    "per_claim": 168.95263438,
    "is_generic": false
   },
   {
    "brand": "Enilloring",
    "claims": 1126,
    "per_claim": 171.88686501,
    "is_generic": false
   },
   {
    "brand": "Haloette",
    "claims": 913,
    "per_claim": 214.29728368,
    "is_generic": false
   },
   {
    "brand": "Nuvaring",
    "claims": 520,
    "per_claim": 322.91817308,
    "is_generic": false
   }
  ],
  "per_claim": 196.08589241138293
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": null,
 "exposure": null,
 "scores": {
  "safety": {
   "score": 58,
   "letter": "D",
   "why": [
    "Graded by its riskiest ingredient, ethinyl estradiol (58)",
    "Carries an FDA boxed warning, the strongest warning the FDA issues (-30)",
    "Death appears in 2.6x the share of reports seen across all of FAERS (-12)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 38,
   "letter": "F",
   "why": [
    "Graded by its riskiest ingredient, ethinyl estradiol (38)",
    "187 randomized trials and 2 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)",
    "Only 32% of completed registered trials posted results (-15)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 81,
   "letter": "B",
   "why": [
    "Graded by its riskiest ingredient, etonogestrel (81)",
    "No recalls on record since 2016",
    "REMS program in force (-10)",
    "4 label changes approved since 2021 (-4)",
    "Label lists recent major changes to warnings or indications (-5)"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 70,
   "letter": "C",
   "why": [
    "Graded by its riskiest ingredient, etonogestrel (70)",
    "Pharma paid doctors $2,184,034 tied to this drug last year (-30)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "Graded by its riskiest ingredient, ethinyl estradiol (70)",
    "No generic version approved: brand-only pricing (-30)",
    "10 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 59,
 "grade": "D",
 "questions": [
  "This is a fixed combination of ethinyl estradiol and etonogestrel. Why both together, instead of only the one I need?",
  "This drug carries a boxed warning. Which specific risk does it cover, and does it apply to me?",
  "The most-reported problems in FDA's adverse event data are pain, lower respiratory tract infection, pruritus, rash. How would we recognize and handle those?",
  "Why this one over chlorotrianisene, diethylstilbestrol, estetrol? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)",
  "This drug has a REMS safety program. What monitoring does that require from us?",
  "The most-reported problems in FDA's adverse event data are no adverse event, complication associated with device, product quality issue, device breakage. How would we recognize and handle those?",
  "Why this one over desogestrel, drospirenone, levonorgestrel? What would make you pick one of those instead?",
  "The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?"
 ]
}